All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F13%3A43907345" target="_blank" >RIV/00216208:11120/13:43907345 - isvavai.cz</a>

  • Alternative codes found

    RIV/00064173:_____/13:N0000001

  • Result on the web

    <a href="http://dx.doi.org/10.1136/heartjnl-2012-303368" target="_blank" >http://dx.doi.org/10.1136/heartjnl-2012-303368</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1136/heartjnl-2012-303368" target="_blank" >10.1136/heartjnl-2012-303368</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program

  • Original language description

    Overlapping first generation sirolimus- and paclitaxel-eluting stents are associated with persistent inflammation, fibrin deposition and delayed endothelialisation in preclinical models, and adverse angiographic and clinical outcomes-including death andmyocardial infarction (MI)-in clinical studies. To establish as to whether there are any safety concerns with newer generation drug-eluting stents (DES). Propensity score adjustment of baseline anatomical and clinical characteristics were used to compareclinical outcomes (Kaplan-Meier estimates) between patients implanted with overlapping DES (Resolute zotarolimus-eluting stent (R-ZES) or R-ZES/other DES) against no overlapping DES. Additionally, angiographic outcomes for overlapping R-ZES and everolimus-eluting stents were evaluated in the randomised RESOLUTE All-Comers Trial. Patient level data from five controlled studies of the RESOLUTE Global Clinical Program evaluating the R-ZES were pooled. Enrolment criteria were generally unre

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FA - Cardiovascular diseases including cardio-surgery

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2013

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Heart

  • ISSN

    1355-6037

  • e-ISSN

  • Volume of the periodical

    99

  • Issue of the periodical within the volume

    9

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    8

  • Pages from-to

    626-633

  • UT code for WoS article

    000317110400007

  • EID of the result in the Scopus database